Anavex officer gets 12,500 performance stock options

Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026.

Rhea-AI Filing Summary

Anavex Life Sciences Corp. reported that its PFO & Treasurer, Sandra Boenisch, acquired a derivative security in the form of a stock option on January 6, 2026. The option covers 12,500 shares of common stock at an exercise price of $8.58 per share and is exercisable until March 31, 2035.

The 12,500-share tranche comes from an earlier option grant dated March 31, 2025 for 50,000 shares that vests in four equal performance-based tranches. One milestone was achieving a second regulatory dialogue for blarcamesine, and meeting this performance criterion triggered vesting of this 12,500-share portion, which Boenisch now holds directly.

Insider Trade Summary

Grant/Award: 12,500 shares

Grant/Award 1 txn

Insider Boenisch Sandra

Role PFO & Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	12,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 12,500 contracts (Direct)

Footnotes (1)

1. F1. On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AVXL report in this Form 4?

The company reported that Sandra Boenisch, its PFO & Treasurer, acquired a stock option covering 12,500 shares of Anavex Life Sciences Corp. common stock.

Who is the reporting person in the AVXL Form 4 filing?

The reporting person is Sandra Boenisch, an officer of Anavex Life Sciences Corp. serving as PFO & Treasurer.

How many AVXL shares are covered by the new stock option?

The reported stock option covers 12,500 shares of Anavex Life Sciences Corp. common stock, which Boenisch beneficially owns following the transaction.

What is the exercise price and term of the AVXL stock option?

The stock option has an exercise price of $8.58 per share, became exercisable on January 6, 2026, and expires on March 31, 2035.

How does this 12,500-share option relate to Boenisch’s earlier AVXL grant?

On March 31, 2025, Boenisch was granted an option to purchase 50,000 shares, vesting in four equal performance tranches; the current 12,500-share portion vested when a performance milestone was achieved.

What performance milestone triggered vesting of the AVXL option tranche?

One vesting milestone was a second regulatory dialogue for blarcamesine. Meeting this performance criterion caused the option to vest as to 12,500 shares.

Did Sandra Boenisch pay cash to receive this AVXL option grant?

The Form 4 shows the derivative transaction with a per-derivative security price of $0, reflecting a performance-based option vesting rather than an open-market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boenisch Sandra

(Last) (First) (Middle)

650 5TH AVENUE, 20TH FLOOR

(Street)

NEW YORK NY 10111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.58	01/06/2026		A		12,500(1)		01/06/2026	03/31/2035	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

	/s/ Sandra Boenisch	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.